Predictors of treatment failure on second-line antiretroviral therapy among adults in northwest Ethiopia: a multicentre retrospective follow-up study
| Autor: | Wubshet M, Addis Alene K, Tadesse Awoke, Adino Tesfahun Tsegaye |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male 0301 basic medicine medicine.medical_specialty Anti-HIV Agents HIV Infections Treatment failure Tertiary Care Centers 03 medical and health sciences 0302 clinical medicine Antiretroviral Therapy Highly Active Internal medicine Weight Loss Epidemiology medicine EPIDEMIOLOGY Humans Treatment Failure 030212 general & internal medicine Stage (cooking) Retrospective Studies business.industry Research Public health Weight change INFECTIOUS DISEASES General Medicine Guideline 030112 virology Antiretroviral therapy CD4 Lymphocyte Count Regimen Physical therapy HIV/AIDS Female Lost to Follow-Up Ethiopia Patient Care PUBLIC HEALTH business Delivery of Health Care Follow-Up Studies |
| Zdroj: | BMJ Open |
| ISSN: | 2044-6055 |
| DOI: | 10.1136/bmjopen-2016-012537 |
| Popis: | Background The number of patients using second-line antiretroviral therapy (ART) has increased over time. In Ethiopia, 1.5% of HIV infected patients on ART are using a second-line regimen and little is known about its effect in this setting. Objective To estimate the rate and predictors of treatment failure on second-line ART among adults living with HIV in northwest Ethiopia. Setting An institution-based retrospective follow-up study was conducted at three tertiary hospitals in northwest Ethiopia from March to May 2015. Participants 356 adult patients participated and 198 (55.6%) were males. Individuals who were on second-line ART for at least 6 months of treatment were included and the data were collected by reviewing their records. Primary outcome measure The primary outcome was treatment failure defined as immunological failure, clinical failure, death, or lost to follow-up. To assess our outcome, we used the definitions of the WHO 2010 guideline. Result The mean±SD age of participants at switch was 36±8.9 years. The incidence rate of failure was 61.7/1000 person years. The probability of failure at the end of 12 and 24 months were 5.6% and 13.6%, respectively. Out of 67 total failures, 42 (62.7%) occurred in the first 2 years. The significant predictors of failure were found to be: WHO clinical stage IV at switch (adjusted HR (AHR) 2.1, 95% CI 1.1 to 4.1); CD4 count 3 at switch (AHR 2.0, 95% CI 1.2 to 3.5); and weight change (AHR 0.92, 95% CI 0.88 to 0.95). Conclusions The rate of treatment failure was highest during the first 2 years of treatment. WHO clinical stage, CD4 count at switch, and change in weight were found to be predictors of treatment failure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|